NEWS

WIRES

OTHER

Biomoda and Obio Form Strategic Alliance to Expand Lung Cancer Screening Program

"A strategic alliance with Obio gives Biomoda a presence in a state that is recognized as a leader in cancer research and treatment. Ohio's leaders have established programs and funding to attract promising biomedical technologies to the state through innovative public initiatives that support both research and commercialization," said John Cousins, President of Biomoda.

Biomoda currently is conducting clinical trials of its CyPath lung cancer diagnostic assay, an inexpensive, noninvasive test designed to identify early-stage lung cancer by binding to cancer cells and causing them to fluoresce under ultraviolet light. Phase II trials have focused on military veterans who are at least 25 percent more likely to develop lung cancer and die from the disease.

Cousins said that Obio will help Biomoda launch a veterans screening program in Ohio, similar to ones completed in New Mexico and under consideration by the Nebraska Legislature. "We are also identifying sites for the upcoming Phase III trials, and Ohio is home to several world-class comprehensive cancer centers."

Biomoda is seeking Food and Drug Administration (FDA) approval of its screening technology as a Class III medical device. CyPath is currently for investigational use only.

About Biomoda

Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development. Current research and development operations, laboratory functions and administrative offices are located in Albuquerque, NM.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are made as of the date of this document and are subject to change without notice.

Biomoda, Inc.
John Cousins, 505-821-0875